A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.
The Food and Drug Administration (FDA) issued a Public Health Advisory entitled “Suicidal Thinking in Children and Adolescents Being Treated with Strattera (Atomoxetine)” on September 29, 2005. At FDA’s request, the manufacturer subsequently added a boxed warning to the drug’s labeling on November 8, 2005. To evaluate whether the boxed warning for suicidal thinking in atomoxetine’s labeling was associated with a change in the pattern of attention-deficit/hyperactivity disorder (ADHD) medication use. Patients who had an ADHD diagnosis and were prescribed either atomoxetine or stimulants between January 2004 and December 2007 were selected from IMS LifeLink Health Plan Claims database. In this ecologic analysis, the outcome measure is the incident atomoxetine use rate, defined as the proportion of atomoxetine incident users among all initial ADHD pharmacotherapy users. The impact of the boxed warning was evaluated using interrupted time series analysis. A total of 16,311 patients met the definition of incident ADHD medication users. The incident atomoxetine use rate decreased from January 2004 to September 2005 among all age groups (range, −0.45% to −0.74%); and the rate among adult patients decreased by 11.89% (95% confidence interval, 3.05%–20.74%) from September 2005 to November 2005. No long-term impact was detected. Significant decline of the atomoxetine use rate was observed before the boxed warning in all age groups. No significant change was detected in the atomoxetine use rate among targeted children or adolescents after the FDA’s boxed warning concerning suicidal thinking.
28 November 2013 in Pharmacoepidemiology and Drug Safety
Objective: This study investigates the potential association between montelukast use and psychiatric adverse events by monitoring changes in antidepressant medication dispensing rates before and after initiating montelukast. Methods: The primary study group of montelukast initiators was identified using the Wolters Kluwer’s SOURCE Lx® pharmacy claims database (WK). This group included 232 159 patients ≤45 years old who had at least two montelukast prescriptions from 2003 to 2007. Comparison groups comprised of 264 704 fluticasone initiators and 89 635 long-acting β-agonist corticosteroid (LABA/ICS) initiators were also identified. Antidepressant medication dispensing rates in these three groups were determined using WK, and changes in rates before and after the first asthma controller medication prescription date were evaluated using interrupted time-series analysis (ITS). ITS was performed separately for four age categories, with a focus on youth (12–17 years) and young adult (18–24 years). Results: For patients 18–24 years old, antidepressant medication dispensing rates increased significantly after initiating montelukast [1.93% (1.55–2.32%, p < 0.001)] but also after initiating fluticasone and LABA/ICS [1.72% (1.30–2.15%, p < 0.001) and 2.76% (2.35–3.17%, p < 0.001)]. Similar patterns were observed across the three medication groups for other age categories but these differences were not all significant. Conclusions: Small increases in antidepressant medication dispensing rates occurred after initiating montelukast. However, similar increases were observed in the fluticasone and LABA/ICS comparison groups. The results of this study cannot support a specific association between initiation of montelukast treatment and an increase in psychiatric adverse effects.